JP2016520514A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520514A5
JP2016520514A5 JP2016501063A JP2016501063A JP2016520514A5 JP 2016520514 A5 JP2016520514 A5 JP 2016520514A5 JP 2016501063 A JP2016501063 A JP 2016501063A JP 2016501063 A JP2016501063 A JP 2016501063A JP 2016520514 A5 JP2016520514 A5 JP 2016520514A5
Authority
JP
Japan
Prior art keywords
seq
humanized
antigen
binding construct
lcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501063A
Other languages
English (en)
Other versions
JP6815196B2 (ja
JP2016520514A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/022782 external-priority patent/WO2014164553A1/en
Publication of JP2016520514A publication Critical patent/JP2016520514A/ja
Publication of JP2016520514A5 publication Critical patent/JP2016520514A5/ja
Application granted granted Critical
Publication of JP6815196B2 publication Critical patent/JP6815196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. 配列番号３又は６のＨＣＤＲ１のＨＣＤＲ１；
    配列番号３又は６のＨＣＤＲ２のＨＣＤＲ２；
    配列番号３又は６のＨＣＤＲ３のＨＣＤＲ３；
    配列番号９のＬＣＤＲ１のＬＣＤＲ１；
    配列番号９のＬＣＤＲ２のＬＣＤＲ２；及び
    配列番号９のＬＣＤＲ３のＬＣＤＲ３
    を含むヒト化抗原結合性構築物であって、前記抗原結合性構築物はヒト化ミニボディ又はヒト化ｃｙｓ−ダイアボディを含む、ヒト化抗原結合性構築物。
JP2016501063A 2013-03-13 2014-03-10 Ｃｄ８に対する抗原結合性構築物 Active JP6815196B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780286P 2013-03-13 2013-03-13
US61/780,286 2013-03-13
PCT/US2014/022782 WO2014164553A1 (en) 2013-03-13 2014-03-10 Antigen binding constructs to cd8

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018230270A Division JP6856611B2 (ja) 2013-03-13 2018-12-07 Ｃｄ８に対する抗原結合性構築物

Publications (3)

Publication Number Publication Date
JP2016520514A JP2016520514A (ja) 2016-07-14
JP2016520514A5 true JP2016520514A5 (ja) 2017-04-13
JP6815196B2 JP6815196B2 (ja) 2021-01-20

Family

ID=51527868

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501063A Active JP6815196B2 (ja) 2013-03-13 2014-03-10 Ｃｄ８に対する抗原結合性構築物
JP2018230270A Active JP6856611B2 (ja) 2013-03-13 2018-12-07 Ｃｄ８に対する抗原結合性構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018230270A Active JP6856611B2 (ja) 2013-03-13 2018-12-07 Ｃｄ８に対する抗原結合性構築物

Country Status (8)

Country Link
US (6) US10414820B2 (ja)
EP (3) EP2968622B1 (ja)
JP (2) JP6815196B2 (ja)
KR (2) KR20150131208A (ja)
CN (2) CN113045660B (ja)
AU (2) AU2014249243C1 (ja)
CA (1) CA2904969A1 (ja)
WO (1) WO2014164553A1 (ja)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014164553A1 (en) 2013-03-13 2014-10-09 Imaginab, Inc. Antigen binding constructs to cd8
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2015149077A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2016086186A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN109071627B (zh) 2016-02-05 2023-04-04 奥里尼斯生物科学私人有限公司 Cd8结合剂
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
AU2017367734A1 (en) 2016-12-01 2019-06-20 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging
IL268346B2 (en) 2017-02-06 2024-08-01 Orionis Biosciences BV Targeted chimeric proteins and their uses
WO2018147960A1 (en) * 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
US10730944B2 (en) 2017-07-24 2020-08-04 Regeneron Pharmaceuticals, Inc. Anti-CD8 antibodies and uses thereof
CN111511763B (zh) * 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
CA3069992A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Clec9a binding agents and use thereof
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
KR102713874B1 (ko) * 2017-08-11 2024-10-10 제넨테크, 인크. 항-cd8 항체 및 이의 용도
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
CA3087529A1 (en) 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
CA3113080A1 (en) 2018-09-28 2020-04-02 Imaginab, Inc. Cd8 imaging constructs and methods of use thereof
KR20210069641A (ko) 2018-10-03 2021-06-11 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CN115103633B (zh) * 2019-12-05 2023-09-12 伊麦吉纳博公司 使用多种成像剂的成像方法
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CN116723857A (zh) 2020-07-21 2023-09-08 苏州智核生物医药科技有限公司 Cd8结合多肽及其用途
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
JP2024501771A (ja) * 2021-01-06 2024-01-15 パレオン ファーマシューティカルズ インコーポレイテッド 抗ｐｄ－ｌ１抗体及びその融合タンパク質
US20220241328A1 (en) 2021-01-11 2022-08-04 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
JP2024505600A (ja) 2021-02-03 2024-02-06 モーツァルト セラピューティクス， インコーポレイテッド 結合剤およびそれを使用する方法
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
IL307544A (en) 2021-04-08 2023-12-01 Sana Biotechnology Inc Constructs of CD8-specific antibodies and preparations thereof
EP4377338A2 (en) 2021-07-27 2024-06-05 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024188355A1 (en) 2023-03-16 2024-09-19 Itabmed Biopharmaceutical (Shanghai) Co., Ltd. Multispecific antigen binding proteins and uses thereof
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
CN118286410B (zh) * 2024-06-06 2024-09-13 山东兴瑞生物科技有限公司 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4709015A (en) 1979-12-04 1987-11-24 Ortho Pharmaceutical Corporation Monoclonal antibody to human suppressor T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
WO1997000271A1 (en) * 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
JP4191258B2 (ja) 1997-04-07 2008-12-03 ジェネンテック・インコーポレーテッド ヒト化抗体およびヒト化抗体の形成法
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
AU2003223683A1 (en) * 2002-04-22 2003-11-03 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
US7273608B2 (en) * 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
US8202509B2 (en) 2007-01-11 2012-06-19 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
JP5309775B2 (ja) 2008-08-07 2013-10-09 セイコーエプソン株式会社 放電灯の駆動装置および駆動方法、光源装置並びに画像表示装置
US8399630B2 (en) * 2008-08-20 2013-03-19 Centocor Ortho Biotech Inc. Engineered anti-IL-13 antibodies, compositions, methods and uses
UA102722C2 (en) 2009-01-29 2013-08-12 Эббви Инк. Il-1 binding proteins
CN102753194B (zh) 2009-12-02 2015-07-08 伊麦吉纳博公司 靶向人前列腺特异性膜抗原的j591微抗体和双抗体
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
WO2013020074A2 (en) 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
WO2014025828A1 (en) 2012-08-06 2014-02-13 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
WO2014164553A1 (en) 2013-03-13 2014-10-09 Imaginab, Inc. Antigen binding constructs to cd8
CN109476721B (zh) 2016-04-04 2022-06-28 英蒂分子公司 Cd8-特异性捕获剂、组合物及使用和制备方法

Similar Documents

Publication Publication Date Title
JP2016520514A5 (ja)
IL290425A (en) Humanized, murine or chimeric anti-cd47 monoclonal antibodies
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
JP2018021031A5 (ja)
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
NZ706147A (en) Anti-cd38 antibody and melphalan for the treatment of multiple myeloma
NZ740221A (en) St2l antagonists and methods of use
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
WO2015153513A8 (en) Anti-ox40 antibodies and methods of use
WO2015109131A3 (en) Bi-specific cd3 and cd19 antigen-binding constructs
EP3204422A4 (en) Humanized anti-ox40 antibodies and uses thereof
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
WO2015091853A3 (en) Human anti-cd40 human antibodies
WO2015010100A3 (en) Humanized antibodies with ultralong complementarity determining regions
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
WO2014152006A3 (en) Anti-hepcidin antibodies and uses thereof
JP2015530399A5 (ja)
MX2023006416A (es) Anticuerpos, usos y metodos.
WO2015017146A3 (en) Antibodies with ultralong complementarity determining regions
NZ604464A (en) Anti-vegf antibodies and uses thereof
WO2016166296A3 (en) Humanized anti-axl antibodies
WO2017021539A3 (en) Novel anti-human gpvi antibodies and uses thereof
WO2015107331A3 (en) Anti-light antibodies